Estrella Immunopharma (NASDAQ:ESLA) Releases Quarterly Earnings Results

Estrella Immunopharma (NASDAQ:ESLA) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, FiscalAI reports.

Estrella Immunopharma Stock Up 3.3%

Estrella Immunopharma stock traded up $0.07 during midday trading on Thursday, hitting $2.17. 104,611 shares of the stock were exchanged, compared to its average volume of 147,605. Estrella Immunopharma has a 52 week low of $0.73 and a 52 week high of $3.15. The company has a fifty day simple moving average of $1.68 and a two-hundred day simple moving average of $1.21. The stock has a market capitalization of $80.44 million, a PE ratio of -7.23 and a beta of 0.52.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Friday, October 31st. D. Boral Capital reiterated a “buy” rating and issued a $16.00 target price on shares of Estrella Immunopharma in a research note on Monday, November 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Estrella Immunopharma presently has a consensus rating of “Hold” and a consensus price target of $16.00.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.